January 25, 2014 /
MS Drug Therapies
June 23, 2014
http://www.researchandmarkets.com/research/t2hnb5/generic_drug) has announced the addition of the “Generic Drug Opportunity Assessment – Fingolimod (Gilenya)” report to their offering.
Gilenya (fingolimod) is the first in a new class of multiple sclerosis (MS) therapies called sphingosine 1-phosphate receptor modulators and the first oral therapy approved to treat relapsing-remitting MS (RRMS). In the US, Gilenya is indicated for relapsing forms of MS. In the EU, Gilenya is indicated for adult patients with highly active RRMS defined as either high disease activity despite treatment with beta interferon, or rapidly evolving severe RRMS. A Phase II/III study of Gilenya in patients with chronic inflammatory demyelinating polyradiculoneuropathy was initiated in 2012. In 2012 Gilenya continued to show rapid growth as the first once-daily oral therapy approved for relapsing remitting and/or relapsing forms of multiple sclerosis (MS and RRMS) in adult patients, and achieved $1.2 billion in annual sales.
The Market
The Multiple Sclerosis market has been dominated by injectables – interferons and more recently Teva’s Copaxone. It is believed that interferon medications such as Rebif, Betaferon, and Avonex are effective against MS because they help regulate the immune system to decrease attacks on myelin. Rebif has been shown to be effective in treating patients with relapsing-remitting MS. The interferons have been shown to reduce relapses in relapsing-remitting MS, though not for primary progressive multiple sclerosis, for which there are currently no disease-modifying treatments proven to be effective.
……..
To comment – click the comment link shown below
…….
Share our Articles with others
…….
Share our Articles with others
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- Pre-recorded video on Intimacy and MS + Q&A – with Aaron Boster, MD
- video: What Is a Multiple Sclerosis Attack? Signs, Treatments and Prevention
- What is Multiple Sclerosis? A Video Overview of MS Causes, Symptoms, Treatments & Research
- Which Statin Is Right for You?
- Capability–Opportunity–Motivation–Behavior (COM-B) Correlates of Physical Activity in People with Multiple Sclerosis Who Have Analogue Generalized Anxiety Disorder
- Workplace lubricant exposure linked to higher odds of MS in new study
- Low-fat diet may help reduce fatigue in MS, suggested in a new trial analysis
- What Are the Symptoms of Low Magnesium, and How Do You Treat It?
- Christina Applegate MS Misdiagnosis Explained by a Neurologist
- Press release: TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
- Falling Into Fall: How the Changing Seasons Affect My MS Symptoms
- Moving past the heat and shifting expectations as the seasons change
- Blood levels of key protein may help predict MS progression
- Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
- Florida Atlantic University (FAU) lands NIH grant to study new cells that may help repair nerve damage
- Understanding Infusion Treatments for Multiple Sclerosis
- Effect of intrathecal injection of mesenchymal stem cell-neural progenitors on cerebrospinal fluid biomarkers in progressive multiple sclerosis
- Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates
- Dealing with MS Numbness
- CAR T-cell deaths in subjects with autoimmunity

